Crinetics Pharmaceuticals, Inc. (CRNX)

Market Cap	3.46B
Revenue (ttm)	1.04M
Net Income (ttm)	-277.91M
Shares Out	92.74M
EPS (ttm)	-3.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	737,043
Open	37.02
Previous Close	36.48
Day's Range	36.80 - 37.96
52-Week Range	35.24 - 62.53
Beta	0.60
Analysts	Strong Buy
Price Target	74.40 (+99.2%)
Earnings Date	Feb 26, 2025

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2018
• Employees: 290
• Stock Exchange: NASDAQ
• Ticker Symbol: CRNX
• Website: https://www.crinetics.com

Financial Performance

In 2023, Crinetics Pharmaceuticals's revenue was $4.01 million, a decrease of -15.28% compared to the previous year's $4.74 million. Losses were -$214.53 million, 30.9% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price forecast is $74.4, which is an increase of 99.20% from the latest price.

Price Target

$74.4

(99.20% upside)

Analyst Consensus: Strong Buy